IlluminOss Medical Inc. Appoints Manny Avila As Chief Executive Officer

IlluminOss Medical, a commercial-stage medical device company focused on minimally invasive orthopedic fracture repair, has named Manny Avila as its chief executive officer. Avila brings more than two decades of experience in medical device sales, operations and business management to IlluminOss. His proven leadership abilities will benefit the company as it continues to grow in global markets and move towards FDA approval domestically.

Mr. Avila joins IlluminOss from OmniGuide, where he was global vice president of sales and marketing. Prior to that, Avila served as vice president of commercial operations, surgical solutions Europe for Covidien. He has also held management roles at Aspect Medical, Synthes and Haemonetics.

"We are pleased to bring someone of Mr. Avila's caliber on at such a pivotal time for IlluminOss," said Robert Rabiner, founder and chief technical officer, IlluminOss Medical. "Through his extensive experience in the medical device industry, he has cultivated the knowledge and skillset we are looking for to drive adoption of the IlluminOss System as a minimally invasive alternative to traditional facture repair methods."

The IlluminOss System has proven to be extremely successful in the treatment of complex fractures in over a thousand patients in Europe, where it is commercially available and has been in clinical use since 2010. Using a light-curable polymer, contained within an expandable balloon catheter, IlluminOss' intramedullary patient-conforming implant achieves the repair and stabilization of fractures. Benefits observed have included smaller incisions, shorter procedure times, and more rapid post-procedure patient mobility with reduced hospital stays and lower complication rates.

"We are confident that IlluminOss' technology has what it takes to redefine and improve the way complex fracture treatment can be approached," said Fouad Azzam, Ph.D., Board of Directors, IlluminOss Medical. "We have been very selective in the development of our team to ensure that we have the right people at the helm to continue to advance IlluminOss, and Mr. Avila will be a valuable addition."

IlluminOss is currently executing on its first U.S. trial towards FDA approval. The U.S. Lightfix clinical trial applies IlluminOss' groundbreaking approach to orthopedic fracture repair to the treatment of impending and pathologic fractures in the humerus due to metastatic bone disease.

About IlluminOss

IlluminOss Medical is a privately held, commercial-stage medical device company focused on designing, developing and marketing orthopedic fracture repair products that leverage its proprietary bone stabilization technology, the IlluminOss System. This minimally invasive technology allows for fracture fixation through patient-specific intramedullary implants. The system utilizes a light-curable polymer, contained within an expandable balloon catheter, to achieve bone stabilization. The revolutionary procedure is made through a small percutaneous surgical approach, providing patients and clinicians with a fast, patient-specific method of orthopedic bone stabilization. The company currently markets its products in international countries under a CE Mark for approved clinical applications through both a direct sales force and distribution networks.

The IlluminOss products are Investigational Devices; limited by Federal law to Investigational Use and are not approved for sale in the USA.

Media Contact:
Jordan Bouclin
SVM Public Relations
Email Contact
(401)490-9700

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.